Characteristics of de novo cancer in liver transplant recipients

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Characteristics of de novo cancer in liver transplant recipients. / Riis, Tine Holm; Møller, Dina Leth; Høgh, Julie; Knudsen, Andreas Dehlbæk; Rostved, Andreas Arendtsen; Akdag, Delal; Kirkby, Nikolai; Lassen, Ulrik; Rasmussen, Allan; Hillingsø, Jens G.; Pommergaard, Hans Christian.

In: APMIS, Vol. 131, No. 4, 2023, p. 135-141.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Riis, TH, Møller, DL, Høgh, J, Knudsen, AD, Rostved, AA, Akdag, D, Kirkby, N, Lassen, U, Rasmussen, A, Hillingsø, JG & Pommergaard, HC 2023, 'Characteristics of de novo cancer in liver transplant recipients', APMIS, vol. 131, no. 4, pp. 135-141. https://doi.org/10.1111/apm.13296

APA

Riis, T. H., Møller, D. L., Høgh, J., Knudsen, A. D., Rostved, A. A., Akdag, D., Kirkby, N., Lassen, U., Rasmussen, A., Hillingsø, J. G., & Pommergaard, H. C. (2023). Characteristics of de novo cancer in liver transplant recipients. APMIS, 131(4), 135-141. https://doi.org/10.1111/apm.13296

Vancouver

Riis TH, Møller DL, Høgh J, Knudsen AD, Rostved AA, Akdag D et al. Characteristics of de novo cancer in liver transplant recipients. APMIS. 2023;131(4):135-141. https://doi.org/10.1111/apm.13296

Author

Riis, Tine Holm ; Møller, Dina Leth ; Høgh, Julie ; Knudsen, Andreas Dehlbæk ; Rostved, Andreas Arendtsen ; Akdag, Delal ; Kirkby, Nikolai ; Lassen, Ulrik ; Rasmussen, Allan ; Hillingsø, Jens G. ; Pommergaard, Hans Christian. / Characteristics of de novo cancer in liver transplant recipients. In: APMIS. 2023 ; Vol. 131, No. 4. pp. 135-141.

Bibtex

@article{c85c36aa07f445d38894a0a0b938e864,

title = "Characteristics of de novo cancer in liver transplant recipients",

abstract = "Liver transplant recipients receive immunosuppressive treatment to avoid organ rejection, increasing the risk of developing de novo cancer after transplantation. We investigated the cumulative incidence of de novo cancer in a cohort of Danish liver transplant recipients. The study was a retrospective cohort study of adult liver transplant recipients transplanted at Rigshospitalet, Copenhagen, Denmark, between January 1, 2010, and December 31, 2019. De novo cancer was defined as cancer arising at least 30 days after liver transplantation, excluding relapses from prior cancers and donor-derived cancers. We determined the incidence of de novo cancer in the cohort using the Aalen-Johansen estimator, with death and retransplantation as competing risks. We included 389 liver transplant recipients and identified 47 recipients (12%) with de novo cancer after liver transplantation, including 25 recipients with non-melanoma skin cancers. The cumulative incidences at 5 years after liver transplantation for all cancers and non-skin cancers were 10.7% and 4.9%, respectively. De novo cancer after liver transplantation is relatively common, with the majority being non-melanoma skin cancer. Future studies of sufficient size are needed to identify risk factors for de novo cancer after liver transplantation.",

keywords = "de novo cancer, immunosuppressive treatment, Liver transplantation",

author = "Riis, {Tine Holm} and M{\o}ller, {Dina Leth} and Julie H{\o}gh and Knudsen, {Andreas Dehlb{\ae}k} and Rostved, {Andreas Arendtsen} and Delal Akdag and Nikolai Kirkby and Ulrik Lassen and Allan Rasmussen and Hillings{\o}, {Jens G.} and Pommergaard, {Hans Christian}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology.",

year = "2023",

doi = "10.1111/apm.13296",

language = "English",

volume = "131",

pages = "135--141",

journal = "A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica",

issn = "0903-4641",

publisher = "Wiley Online",

number = "4",

}

RIS

TY - JOUR

T1 - Characteristics of de novo cancer in liver transplant recipients

AU - Riis, Tine Holm

AU - Møller, Dina Leth

AU - Høgh, Julie

AU - Knudsen, Andreas Dehlbæk

AU - Rostved, Andreas Arendtsen

AU - Akdag, Delal

AU - Kirkby, Nikolai

AU - Lassen, Ulrik

AU - Rasmussen, Allan

AU - Hillingsø, Jens G.

AU - Pommergaard, Hans Christian

PY - 2023

Y1 - 2023

N2 - Liver transplant recipients receive immunosuppressive treatment to avoid organ rejection, increasing the risk of developing de novo cancer after transplantation. We investigated the cumulative incidence of de novo cancer in a cohort of Danish liver transplant recipients. The study was a retrospective cohort study of adult liver transplant recipients transplanted at Rigshospitalet, Copenhagen, Denmark, between January 1, 2010, and December 31, 2019. De novo cancer was defined as cancer arising at least 30 days after liver transplantation, excluding relapses from prior cancers and donor-derived cancers. We determined the incidence of de novo cancer in the cohort using the Aalen-Johansen estimator, with death and retransplantation as competing risks. We included 389 liver transplant recipients and identified 47 recipients (12%) with de novo cancer after liver transplantation, including 25 recipients with non-melanoma skin cancers. The cumulative incidences at 5 years after liver transplantation for all cancers and non-skin cancers were 10.7% and 4.9%, respectively. De novo cancer after liver transplantation is relatively common, with the majority being non-melanoma skin cancer. Future studies of sufficient size are needed to identify risk factors for de novo cancer after liver transplantation.

AB - Liver transplant recipients receive immunosuppressive treatment to avoid organ rejection, increasing the risk of developing de novo cancer after transplantation. We investigated the cumulative incidence of de novo cancer in a cohort of Danish liver transplant recipients. The study was a retrospective cohort study of adult liver transplant recipients transplanted at Rigshospitalet, Copenhagen, Denmark, between January 1, 2010, and December 31, 2019. De novo cancer was defined as cancer arising at least 30 days after liver transplantation, excluding relapses from prior cancers and donor-derived cancers. We determined the incidence of de novo cancer in the cohort using the Aalen-Johansen estimator, with death and retransplantation as competing risks. We included 389 liver transplant recipients and identified 47 recipients (12%) with de novo cancer after liver transplantation, including 25 recipients with non-melanoma skin cancers. The cumulative incidences at 5 years after liver transplantation for all cancers and non-skin cancers were 10.7% and 4.9%, respectively. De novo cancer after liver transplantation is relatively common, with the majority being non-melanoma skin cancer. Future studies of sufficient size are needed to identify risk factors for de novo cancer after liver transplantation.

KW - de novo cancer

KW - immunosuppressive treatment

KW - Liver transplantation

U2 - 10.1111/apm.13296

DO - 10.1111/apm.13296

M3 - Journal article

C2 - 36680559

AN - SCOPUS:85148009508

VL - 131

SP - 135

EP - 141

JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

SN - 0903-4641

IS - 4

ER -

ID: 359549465